Represents the additional term provided for standard-of-care treatment under collaborative agreement.

No definition available.

Name:	rdus_CollaborativeAgreementAdditionalTermProvidedForStandardOfCareTreatment
Namespace Prefix:	rdus_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the amount of euro-denominated payments required over the course of the Clinical Study under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeAgreementAmountOfEuroDenominatedPaymentsRequiredOverCourseOfClinicalStudy
Namespace Prefix:	rdus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the amount of U.S. dollar-denominated payments required over the course of the Clinical Study under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeAgreementAmountOfUSDollarDenominatedPaymentsRequiredOverCourseOfClinicalStudy
Namespace Prefix:	rdus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Agreement Initial Term Provided for Standard of Care Treatment

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeAgreementInitialTermProvidedforStandardofCareTreatment
Namespace Prefix:	rdus_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rdus_CollaborativeArrangementsTypeOfAgreementAxis=rdus_LetterOfIntentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rdus_ClinicalStudyByPhaseAxis=rdus_AbaloparatideSCPhase3ClinicalExtensionStudyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rdus_NordicMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rdus_CollaborativeArrangementsTypeOfAgreementAxis=rdus_WorkStatementNB3AmendmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rdus_CollaborativeArrangementsTypeOfAgreementAxis=rdus_WorkStatementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Research Agreements (Details) $ in Thousands, € in Millions			1 Months Ended		3 Months Ended
Research Agreements (Details) $ in Thousands, € in Millions	Feb. 21, 2013 USD ($)	Feb. 21, 2013 EUR (€)	Apr. 30, 2015 USD ($)	Apr. 30, 2015 EUR (€)	Mar. 31, 2017 USD ($)	Mar. 31, 2016 USD ($)
Research Agreements
Research and development expense					$ 19,527	$ 27,483
Clinical Trial Services Agreement \| Letter of Intent \| Abaloparatide-SC Phase 3 Extension Clinical Study \| Nordic
Research Agreements
Collaborative agreement initial term provided for standard of care treatment	6 months	6 months
Additional term provided for standard-of-care treatment	18 months	18 months
Clinical Trial Services Agreement \| NB-3 Amendment \| Abaloparatide-SC Phase 3 Extension Clinical Study \| Nordic \| Maximum
Research Agreements
Amount of euro-denominated payments required over the course of Clinical Trial			$ 4,300	€ 4.1
Clinical Trial Services Agreement \| Clinical Trial Services Agreement \| Abaloparatide-SC Phase 3 Extension Clinical Study \| Nordic \| Maximum
Research Agreements
Amount of euro-denominated payments required over the course of Clinical Trial	$ 12,500	€ 11.9
Amount of U.S. dollar-denominated payments required over the course of Clinical Trial	$ 1,100